We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bayer blamed a strong euro for some obvious weak spots in its first-quarter numbers, but that explanation just doesn't fly for its consumer health stall...